rafamin (MMH-407) / Materia Medica - LARVOL DELTA

MMH-407-009: Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia (clinicaltrials.gov) - P3 | N=370 | Completed | Sponsor: Materia Medica Holding | Recruiting ➔ Completed | Trial completion date: Dec 2026 ➔ Mar 2025 | Trial primary completion date: Dec 2026 ➔ Mar 2025

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumonia • Respiratory Diseases

The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients (clinicaltrials.gov) - P3 | N=552 | Recruiting | Sponsor: Materia Medica Holding

New P3 trial • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients (clinicaltrials.gov) - P3 | N=771 | Completed | Sponsor: Materia Medica Holding | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years. (clinicaltrials.gov) - P3 | N=374 | Recruiting | Sponsor: Materia Medica Holding

New P3 trial • Infectious Disease

Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis (clinicaltrials.gov) - P3 | N=632 | Recruiting | Sponsor: Materia Medica Holding

New P3 trial

Clinical Trial of the Efficacy and Safety of Raphamin in Combination Treatment of Community-acquired Pneumonia (clinicaltrials.gov) - P3 | N=370 | Recruiting | Sponsor: Materia Medica Holding

New P3 trial • Infectious Disease • Pneumonia • Respiratory Diseases

The effect of etiopathogenetic therapy of COVID-19 on the severity of the disease: results of a multicenter double-blind placebo-controlled randomized trial (PubMed, Ter Arkh) - "Raphamin reduces the risk of progression to a more severe degree of the COVID-19 and significantly shortens the duration of clinical symptoms."

Clinical • Journal • Gene Therapies • Infectious Disease • Novel Coronavirus Disease

Efficacy of Raphamin against Pneumococcal Infection: a Preclinical Study. (PubMed, Bull Exp Biol Med) - "Raphamin monotherapy significantly decreased bacterial load in the lungs in comparison with placebo (p<0.05) which was comparable to the effect in antibiotic alone or combined with Raphamin. Raphamin prevented reproduction of Streptococcus pneumoniae in the lower respiratory tract and its combination with the antibiotic was safe and did not reduce the efficacy of amoxicillin/clavulanic acid."

Journal • Preclinical • Infectious Disease • Pneumococcal Infections • Pneumonia

MMH-407-003: Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old (clinicaltrials.gov) - P3 | N=435 | Completed | Sponsor: Materia Medica Holding | Active, not recruiting ➔ Completed | Trial completion date: Dec 2024 ➔ Jul 2023 | Trial primary completion date: Dec 2024 ➔ Jul 2023

Trial completion • Trial completion date • Trial primary completion date • Infectious Disease

Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients (clinicaltrials.gov) - P3 | N=813 | Active, not recruiting | Sponsor: Materia Medica Holding | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

MMH-407-003: Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old (clinicaltrials.gov) - P3 | N=435 | Active, not recruiting | Sponsor: Materia Medica Holding | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease

MMH-407-003: Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old (clinicaltrials.gov) - P3 | N=400 | Recruiting | Sponsor: Materia Medica Holding | Suspended ➔ Recruiting | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2024

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults (clinicaltrials.gov) - P3 | N=314 | Recruiting | Sponsor: Materia Medica Holding | Suspended ➔ Recruiting | Trial completion date: Dec 2022 ➔ Dec 2024 | Trial primary completion date: Dec 2022 ➔ Dec 2024

Enrollment open • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Respiratory Diseases

Antiviral Activity of Technologically Processed Antibodies to CD4 Receptor against Influenza Infection. (PubMed, Bull Exp Biol Med) - "The reference drug Tamiflu increased mouse survival rate (by 47%), decreased the virus titer in the lungs, and prevented body weight loss (p<0.05 in comparison with the placebo group by all parameters). The intrinsic protective activity of technologically processed antibodies to CD4 receptor was demonstrated, which manifested in a decrease in viral load in the lower respiratory tract and an increase in the survival rate."

Journal • Infectious Disease • Influenza • Respiratory Diseases • CD4

Evaluation of the efficacy and safety of a complex antiviral drug based on antibodies in the treatment of adult patients with acute respiratory viral infection (PubMed, Ter Arkh) - "Raphamin promotes significant decrease, practically by a day, the duration of ARVI, including influenza."

Clinical • Journal • Infectious Disease • Influenza • Respiratory Diseases • CD4 • HLA-DRB1

Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients (clinicaltrials.gov) - P3 | N=838 | Recruiting | Sponsor: Materia Medica Holding

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults (clinicaltrials.gov) - P3 | N=314 | Suspended | Sponsor: Materia Medica Holding | Recruiting ➔ Suspended

Trial suspension • Infectious Disease • Respiratory Diseases

MMH-407-003: Clinical Study of Efficacy and Safety of Rafamin in the Treatment of ARVI in Children 12-18 Years Old (clinicaltrials.gov) - P3 | N=400 | Suspended | Sponsor: Materia Medica Holding | Recruiting ➔ Suspended

Trial suspension • Infectious Disease

Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection (clinicaltrials.gov) - P3; N=240; Completed; Sponsor: Materia Medica Holding; Recruiting ➔ Completed

Trial completion • PCR

Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults (clinicaltrials.gov) - P3; N=314; Recruiting; Sponsor: Materia Medica Holding

Clinical • New P3 trial